Drug intelligence / Profile preview

EXG112

Development stage: Unknown
Lead developer: Exegenesis Bio
Modality: Gene Therapies
Administration: Intrathecal

Overview

EXG112 is an investigational gene therapy developed by Exegenesis Bio for the treatment of chronic pain. It is designed to modulate the Nav1.7 voltage-gated sodium channel (encoded by the SCN9A gene), which is a critical mediator of pain signaling in the peripheral nervous system. By targeting Nav1.7, EXG112 aims to reduce neuronal excitability and alleviate persistent pain symptoms. The therapy is administered via the intrathecal (IT) route, allowing for localized delivery to the spinal environment and associated neural structures. EXG112 is currently in Phase 1 clinical development.

Targets

SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on EXG112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EXG112.

Explore the full profile